CIK 0001855175 · Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
Contineum Therapeutics, Inc.
Sign in to watch- Ticker
- CTNM
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 271467257
- Phone
- (858) 333-5280
- Business address
- 3565 GENERAL ATOMICS COURT, SUITE 200, SAN DIEGO, CA, 92121
- 4 Planned sale Chief Scientific Officer sold 4,170 shares at $13.16 ($54,862)
- 144 Insider Sale of Securities
- SCHEDULE 13G/A Stake Statement of Beneficial Ownership
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Planned sale Chief Scientific Officer sold 4,170 shares at an average $13.12 ($54,694)
- 144 Insider Sale of Securities
- ARS Other Annual Report to Security Holders
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 8-K Event Regulation FD disclosure · Other events
- SCHEDULE 13G Stake Statement of Beneficial Ownership
- 4 Planned sale Chief Scientific Officer sold 4,170 shares at $13.43 ($56,014)
- 144 Insider Sale of Securities
- S-8 Other Securities Offered to Employees in Benefit Plans
- 424B5 Offering Prospectus
- 10-K Report Annual Report
- 8-K Event Results of operations · Other events
- 4 Planned sale Chief Scientific Officer sold 4,170 shares at $15.01 ($62,585)
Page 3 of 11 · 202 filings